Disturbances in the PI3K/Akt pathway, which entail the promotion of metabolic processes crucial for the growth and survival of cancer cells, seem to be an excellent target for targeted therapies, also in the case of gliomas. The gene discussed is AKT1; the disease is central nervous system cancer.